A Novel Lipid-Based MALDI-TOF Assay for the Rapid Detection of Colistin-Resistant <i>Enterobacter</i> Species-Reference-Cited by-同舟云学术

A Novel Lipid-Based MALDI-TOF Assay for the Rapid Detection of Colistin-Resistant Enterobacter Species

Published:2022-02-23 Issue:1 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Smith Richard D.¹²^ORCID,McElheny Christi L.³,Izac Jerilyn R.¹,Gardner Francesca M.¹,Chandler Courtney E.¹,Goodlett David R.⁴⁵,Doi Yohei³⁶⁷^ORCID,Johnson J. Kristie²,Ernst Robert K.¹^ORCID

Affiliation:

1. Department of Microbial Pathogenesis, University of Maryland Baltimore, Baltimore, Maryland, USA

2. Department of Pathology, University of Maryland, Baltimore, Maryland, USA

3. Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

4. Department of Biochemistry & Microbiology, University of Victoria, Victoria, British Columbia, Canada

5. University of Gdansk, International Centre for Cancer Vaccine Science, Gdansk, Poland

6. Department of Microbiology, Fujita Health University, Toyoake, Aichi, Japan

7. Department of Infectious Diseases, Fujita Health University, Toyoake, Aichi, Japan

Abstract

In this study, we develop a novel method for identifying colistin resistance in Enterobacter species and Klebsiella aerogenes without performing antimicrobial susceptibility testing. Typically, susceptibility testing requires an additional 24 to 48 h, while the MS assay described in this study allows for resistant identifications in under 1 h after initial culture.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01445-21

Reference52 articles.

1. Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance

2. The etiology of urinary tract infection: Traditional and emerging pathogens

3. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis